Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor
作者机构：Department of Gastrointestinal SurgeryHarbin Medical University Cancer HospitalHarbin 150081Heilongjiang ProvinceChina Department of RadiologyHarbin Medical University Cancer HospitalHarbin 150081Heilongjiang ProvinceChina
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2024年第30卷第8期
页 面：863-880页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：This study was approved by the Ethics Committee of Harbin Medical University Cancer Hospital
主 题：Gastric cancer Sarcopenia Myosteatosis,Immune checkpoint inhibitor Prognostic factor Overall survival Progression-free survival
摘 要：BACKGROUND The development and progression of gastric cancer(GC)are closely linked to the nutritional status of *** immunotherapy has been demonstrated to be clinically effective,the relationships of sarcopenia and myosteatosis with the use of immune checkpoint inhibitors(ICIs)in patients with gastric cancer remain to be *** We performed a retrospective study of patients who were undergoing immuno-therapy for *** the evaluation of sarcopenia,the optimal cut-off value for the skeletal muscle index was established using receiver operating characteristic analysis of data obtained from pre-treatment computed tomography images at the L3 vertebral *** was defined using the mean skeletal muscle density(SMD),with a threshold value of41 Hounsfield units(HU)for patients with a body mass index(BMI)25 kg/m^(2)and33 HU for those with a BMI≥25 kg/m^(2).The log-rank test was used to compare progression-free survival(PFS)and overall survival(OS),and a Cox proportional hazard model was used to identify prognostic *** were developed to predict the PFS and OS of patients on the basis of the results of multivariate *** We studied 115 patients who were undergoing ICI therapy for GC,of whom 27.4%had sarcopenia and 29.8%had *** with sarcopenia or myosteatosis had significantly shorter PFS and OS than those without these ***,both sarcopenia and myosteatosis were found to be independent predictors of PFS and OS in patients with GC administering an *** prediction models created for PFS and OS were associated with C-indexes of 0.758 and 0.781,*** The presence of sarcopenia or myosteatosis is a reliable predictor of the clinical outcomes of patients with GC who are undergoing treatment with an ICI.
维普期刊数据库